A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk
Authors
Keywords
-
Journal
ONCOGENE
Volume 34, Issue 40, Pages 5198-5205
Publisher
Springer Nature
Online
2015-01-26
DOI
10.1038/onc.2014.443
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Age of Diagnosis of Breast Cancer in China: Almost 10 Years Earlier than in the United States and the European Union
- (2015) Qing-Kun Song et al. Asian Pacific Journal of Cancer Prevention
- Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin
- (2014) Abdul Hameed Baloch et al. MOLECULAR BIOLOGY REPORTS
- About 1% of the breast and ovarian Spanish families testing negative forBRCA1andBRCA2are carriers ofRAD51Dpathogenic variants
- (2013) Sara Gutiérrez-Enríquez et al. INTERNATIONAL JOURNAL OF CANCER
- DNA repair genes are selectively mutated in diffuse large B cell lymphomas
- (2013) Noel FCC de Miranda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Hereditary Breast Cancer: The Era of New Susceptibility Genes
- (2013) Paraskevi Apostolou et al. Biomed Research International
- The CHEK2 I157T Variant and Breast Cancer Susceptibility: A Systematic Review and Meta-analysis
- (2012) Chuan Liu et al. Asian Pacific Journal of Cancer Prevention
- DNA Damage Response and Inflammatory Signaling Limit the MLL-ENL-Induced Leukemogenesis In Vivo
- (2012) Sylvia Takacova et al. CANCER CELL
- Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families
- (2012) Ana Osorio et al. HUMAN MOLECULAR GENETICS
- Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer
- (2011) Cezary Cybulski et al. JOURNAL OF CLINICAL ONCOLOGY
- A mammalian functional-genetic approach to characterizing cancer therapeutics
- (2010) Hai Jiang et al. Nature Chemical Biology
- Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
- (2010) Alfons Meindl et al. NATURE GENETICS
- Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China
- (2009) A-Yong Cao et al. BREAST CANCER RESEARCH AND TREATMENT
- Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response
- (2009) Travis H. Stracker et al. DNA REPAIR
- The combined status of ATM and p53 link tumor development with therapeutic response
- (2009) H. Jiang et al. GENES & DEVELOPMENT
- Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase
- (2009) Zhenjian Cai et al. MOLECULAR CELL
- Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: Not present in the Chinese familial breast cancer population
- (2008) Wang Chen et al. ADVANCES IN THERAPY
- Identification of a novel CHEK2variant and assessment of its contribution to the risk of breast cancer in French Canadian women
- (2008) David J Novak et al. BMC CANCER
- CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls
- (2008) Maren Weischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer in Chinese Women Younger than Age 40: Are They Different from Their Older Counterparts?
- (2008) Ava Kwong et al. WORLD JOURNAL OF SURGERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now